Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by Zacks Investment Research

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $6.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 13.21% from the stock’s current price.

According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “

Separately, ValuEngine downgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th.

Shares of NASDAQ:CPIX opened at $5.30 on Wednesday. The company’s fifty day moving average is $5.37 and its two-hundred day moving average is $5.79. The company has a quick ratio of 1.85, a current ratio of 2.33 and a debt-to-equity ratio of 0.37. Cumberland Pharmaceuticals has a 12-month low of $4.70 and a 12-month high of $7.00. The company has a market cap of $83.02 million, a P/E ratio of -44.17 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.02. Cumberland Pharmaceuticals had a negative net margin of 9.87% and a positive return on equity of 5.04%. The company had revenue of $11.58 million for the quarter, compared to the consensus estimate of $12.59 million. Equities research analysts anticipate that Cumberland Pharmaceuticals will post 0.31 earnings per share for the current year.

In other Cumberland Pharmaceuticals news, Director Gordon R. Bernard sold 6,309 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $5.46, for a total transaction of $34,447.14. Following the sale, the director now directly owns 41,862 shares of the company’s stock, valued at approximately $228,566.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have acquired 2,325 shares of company stock worth $12,446 and have sold 32,669 shares worth $176,120. 39.38% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of Cumberland Pharmaceuticals by 13.0% in the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after acquiring an additional 50,800 shares during the last quarter. BlackRock Inc. increased its stake in shares of Cumberland Pharmaceuticals by 17.2% in the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after acquiring an additional 48,753 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Cumberland Pharmaceuticals by 6.9% in the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after acquiring an additional 6,765 shares during the last quarter. Dalton Greiner Hartman Maher & Co. acquired a new position in shares of Cumberland Pharmaceuticals in the third quarter worth $528,000. Finally, Bailard Inc. acquired a new position in shares of Cumberland Pharmaceuticals in the second quarter worth $92,000. 31.65% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Featured Story: What is a management fee?

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.